DISCO Pharmaceuticals (“DISCO“) announced a strategic collaboration and option‑to‑license agreement with AbbVie (NYSE: ABBV) to discover and develop novel AND‑gated bispecific therapeutics for solid tumors with high unmet medical need. Under the terms, DISCO will receive USD 40 million in upfront payments and is eligible for up to USD 2.5 billion in option, development and other milestone payments, plus tiered royalties on worldwide net sales.
Deal Snapshot
| Item | Detail |
|---|---|
| Parties | DISCO Pharmaceuticals (private) and AbbVie (NYSE: ABBV) |
| Announcement Date | 19 November 2026 |
| Deal Type | Strategic collaboration and option‑to‑license agreement |
| Focus | Discovery and development of AND‑gated bispecific therapeutics for solid tumors with high unmet medical need |
| Upfront Payments | USD 40 million |
| Milestone Payments | Up to USD 2.5 billion in option, development and other milestones |
| Royalties | Tiered royalties on worldwide net sales |
Platform Profile – DISCOtech & AND‑Gated Design
- Company Focus: DISCO is advancing a differentiated pipeline of highly selective, AND‑gated therapeutics for hard‑to‑treat tumors.
- Target Discovery: Through its disruptive DISCOtech platform, the company uncovers novel cell surface target pairs that form the basis of its AND‑gated design logic.
- Modalities: DISCO is designing AND‑gated antibody‑drug conjugates (ADCs) and T‑cell engagers built on the discovered target pairs.
- Mechanism Advantage: AND‑gated (Boolean “AND” logic) therapeutics require simultaneous recognition of two targets to activate, offering the potential for unprecedented specificity and a broad therapeutic window to drive potent anti‑tumor activity while sparing healthy tissue expressing either target alone.
Strategic Rationale – Bispecifics in Solid Tumors
- Unmet Need: Solid tumors account for the majority of cancer mortality, and many remain refractory to existing therapies — driving industry demand for modalities with improved tumor selectivity.
- Convergence of Modalities: ADCs and T‑cell engagers are two of the most active areas in oncology drug development; applying AND‑gated bispecific logic to both aims to overcome the on‑target/off‑tumor toxicity that has limited earlier generations.
- Partnership Model: The collaboration‑plus‑option structure lets AbbVie evaluate DISCO’s platform across discovery before licensing programs — a risk‑mitigated template for engaging next‑generation oncology platform companies.
Market Impact & Outlook
- For AbbVie: The agreement expands the company’s oncology pipeline with AND‑gated bispecific assets targeting solid tumors, complementing its established hematology and solid‑tumor franchises.
- For DISCO: A USD 40 million upfront provides immediate non‑dilutive funding, while the USD 2.5 billion total milestone potential plus tiered worldwide royalties validates the DISCOtech platform and its AND‑gated ADC and T‑cell engager programs.
- Sector Signal: The deal adds to growing Big Pharma appetite for logic‑gated, multi‑specific oncology platforms, as the industry seeks precision approaches that widen the therapeutic window in hard‑to‑treat solid tumors.
- Next Steps: Collaborative discovery and development; AbbVie’s option exercise, program timelines and specific targets were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the collaboration between DISCO Pharmaceuticals and AbbVie, including the discovery and development of AND‑gated bispecific therapeutics, option exercise, milestone payments, regulatory outcomes and commercial potential. Actual results may differ materially due to risks inherent in early‑stage drug discovery, clinical development, regulatory review and competitive dynamics.-Fineline Info & Tech
